Market Overview

UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On Value


In a report published Monday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Theravance (NASDAQ: THRX), but lowered the price target from $12.00 to $7.00.

In the report, Morgan Stanley noted, “In light of the THRX/TBPH split, we are updating our model for Royalty Co. (we do not cover TBPH). We still believe that the farther we are into the ramp of Breo (36 wks on mkt in US) and Anoro (12 wks on mkt in US), the more likely the stock will reflect a) our below consensus estimates, which line up well with current trends, b) a long-term inability to fund the current dividend, and c) the lack of room for add'l financial steps such as more leverage or acquiring a terminal value. To this last point, we note that a de minimus triple combo royalty to THRX (0.95% of sales to start, not currently modeled based on drug risk) is unlikely to serve as a meaningful source of terminal value.”

Theravance closed on Friday at $27.97.

Latest Ratings for THRX

May 2015Cowen & Co.DowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014StifelDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings


Related Articles (THRX)

View Comments and Join the Discussion!

Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings

Latest Ratings

PCTYJMP SecuritiesMaintains220.0
KMBRBC CapitalMaintains147.0
AZEKRBC CapitalMaintains50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at